Sampling variability of liver fibrosis in chronic hepatitis C

By P. Bedossa, D. Dargère, V. Paradis. Hepatology, 2003

2,619 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e3b4ed78d775cb6d9f1af3004a7b820fa34bed91

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “It is important that the size of the needle biopsy specimen is large enough to accurately assess the degree of liver injury, in particular fibrosis [43] (A1).”
Quantifying hepatic shear modulus in vivo using acoustic radiation force. (2008, background): “While core biopsy is considered to be the current gold standard for evaluating liver health, its accuracy is limited by a small sample size, with misdiagnosis in fibrosis staging reported in 20–40% of cases (Ratziu et al., 2005; Regev et al., 2002; Bedossa et al., 2003).”
Computer‐assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient (2009, background): “A liver biopsy should be at least 20 to 25 mm long or contain 11 or more complete portal tracts 3,16 to reliably assess grade and stage in chronic viral hepatitis.”
Accuracy of real‐time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study (2012, background): “Even though still considered the benchmark for validation of noninvasive techniques aimed at assessing degree of liver fibrosis, the accuracy of LB examination is challenged by sampling errors and intra- and interobserver variability.(3,4) Moreover, the METAVIR scoring system does not take into acco”
FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest (2007, methodology): “We reviewed our computerized files of HCV-infected patients attending our unit and selected all the cases corresponding to the following criteria: (1) anti HCV- and HCV-RNA–positive; (2) LB prior to any antiviral therapy; (3) laboratory assessments allowing FIB-4 calculation (AST, ALT, platelet coun”
Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, background): “, bleeding) are problematic.(227-231) Additionally, most clinicians and patients (or their parents) prefer noninvasive alternatives to determine the presence or absence of cirrhosis, particularly in the pediatric population.”
A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “There is no safe threshold for eliminating sampling variability[140]; by analogy withother chronic liver diseases,a core fragment of a minimum of 15 and preferably 25 mm is desirable [139].”